Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial

por Lin, Dan-Yu, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Neuzil, Kathleen M., Corey, Lawrence, Miller, Jacqueline
Publicado 2022

Safety and immunogenicity of three dose levels of an investigational, highly purified Vero cell rabies vaccine: A randomized, controlled, observer-blinded, Phase II study with a si...

por Pichon, Sylvie, Guinet-Morlot, Francoise, Saleh, Jamshid, Essink, Brandon, Pineda-Peña, Andrea-Clemencia, Moureau, Annick, Petit, Celine, Minutello, Ada-Maria
Publicado 2023

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, contro...

por Tricou, Vianney, Essink, Brandon, Ervin, John E., Turner, Mark, Escudero, Ian, Rauscher, Martina, Brose, Manja, Lefevre, Inge, Borkowski, Astrid, Wallace, Derek
Publicado 2023

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults

por August, Allison, Shaw, Christine A, Lee, Heather, Knightly, Conor, Kalidindia, Shiva, Chu, Laurence, Essink, Brandon J, Seger, William, Zaks, Tal, Smolenov, Igor, Panther, Lori
Publicado 2022

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

por Essink, Brandon, Peterson, James, Yacisin, Kari, Lal, Himal, Mirza, Sarah, Xu, Xia, Scully, Ingrid L., Scott, Daniel A., Gruber, William C., Jansen, Kathrin U., Watson, Wendy
Publicado 2021

O23 - Functional effects of an amino-acid based formula with synbiotics in cow’s milk allergic infants

por Burks, Wesley A, Harthoorn, Lucien F, Langford, Jane E, Van Ampting, Marleen T, Goldberg, Steven B, Ong, Peck Y, Essink, Brandon J, Scott, Robert B, Harvey, Bryan M
Publicado 2014

3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older

por Essink, Brandon, Sabharwal, Charu, Xu, Xia, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Pride, Michael W, Scully, Ingrid L, Jansen, Kathrin U, Gruber, William C, Scott, Daniel, Watson, Wendy
Publicado 2020

1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

por Follmann, Dean, Wang, Xiaowei, Gilbert, Peter, Baden, Lindsey R, El Sahly, Hana M, Essink, Brandon, Marovich, Mary, Janes, Holly, Deng, Weiping, Priddy, Frances, Dixit, Avika, Tomassini, Joanne, Das, Rituparna, Miller, Jacqueline, Zhou, Honghong
Publicado 2023

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine

por Peterson, James T, Zareba, Agnieszka M, Fitz-Patrick, David, Essink, Brandon J, Scott, Daniel A, Swanson, Kena A, Chelani, Dhawal, Radley, David, Cooper, David, Jansen, Kathrin U, Dormitzer, Philip R, Gruber, William C, Gurtman, Alejandra
Publicado 2021

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

por Tica, Jelena, Guiñazú, Javier Ruiz, Andrews, Charles P, Davis, Matthew G, Essink, Brandon, Fogarty, Charles, Kerwin, Edward, Leroux-Roels, Isabel, Steenackers, Katie, Vandermeulen, Corinne, David, Marie-Pierre, Dezutter, Nancy, Fissette, Laurence, Koch, Juliane, Mesaros, Narcisa
Publicado 2020

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

por Essink, Brandon, Sabharwal, Charu, Cannon, Kevin, Frenck, Robert, Lal, Himal, Xu, Xia, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Pride, Michael W, Scully, Ingrid L, Jansen, Kathrin U, Gruber, William C, Scott, Daniel A, Watson, Wendy
Publicado 2021

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

por Guiñazú, Javier Ruiz, Tica, Jelena, Andrews, Charles P, Davis, Matthew G, De Smedt, Philippe, Essink, Brandon, Fogarty, Charles, Kerwin, Edward, Leroux-Roels, Isabel, Vandermeulen, Corinne, David, Marie-Pierre, Dezutter, Nancy, De Schrevel, Nathalie, Fissette, Laurence, Mesaros, Narcisa
Publicado 2020

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

por Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R, Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne, Chen, Xing, Chang, Ying, Sutherland, Andrea, Montefiori, David, Girard, Bethany, Edwards, Darin, Feng, Jing, Zhou, Honghong, Baden, Lindsey R, Miller, Jacqueline, Das, Rituparna
Publicado 2022

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

por Chalkias, Spyros, Eder, Frank, Essink, Brandon, Khetan, Shishir, Nestorova, Biliana, Feng, Jing, Chen, Xing, Chang, Ying, Zhou, Honghong, Montefiori, David, Edwards, Darin K., Girard, Bethany, Pajon, Rolando, Dutko, Frank J., Leav, Brett, Walsh, Stephen R., Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Publicado 2022

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

por Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R., Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne E., Chen, Xing, Ying Chang, Sutherland, Andrea, Montefiori, David C., Girard, Bethany, Edwards, Darin K., Jing Feng, Zhou, Honghong, Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Publicado 2023

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents

por Áñez, Germán, Dunkle, Lisa M., Gay, Cynthia L., Kotloff, Karen L., Adelglass, Jeffrey M., Essink, Brandon, Campbell, James D., Cloney-Clark, Shane, Zhu, Mingzhu, Plested, Joyce S., Roychoudhury, Pavitra, Greninger, Alexander L., Patel, Nita, McGarry, Alice, Woo, Wayne, Iksung, Cho, Glenn, Gregory M., Dubovsky, Filip
Publicado 2023

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

por Pajon, Rolando, Paila, Yamuna D., Girard, Bethany, Dixon, Groves, Kacena, Katherine, Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Mullane, Kathleen M., Frank, Ian, Denhan, Douglas, Kerwin, Edward, Zhao, Xiaoping, Ding, Baoyu, Deng, Weiping, Tomassini, Joanne E., Zhou, Honghong, Leav, Brett, Schödel, Florian
Publicado 2022

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

por Chalkias, Spyros, Harper, Charles, Vrbicky, Keith, Walsh, Stephen R., Essink, Brandon, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne E., Chen, Xing, Chang, Ying, Sutherland, Andrea, Montefiori, David C., Girard, Bethany, Edwards, Darin K., Feng, Jing, Zhou, Honghong, Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Publicado 2022

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

por Baden, Lindsey R., El Sahly, Hana M., Essink, Brandon, Follmann, Dean, Neuzil, Kathleen M., August, Allison, Clouting, Heather, Fortier, Gabrielle, Deng, Weiping, Han, Shu, Zhao, Xiaoping, Leav, Brett, Talarico, Carla, Girard, Bethany, Paila, Yamuna D., Tomassini, Joanne E., Schödel, Florian, Pajon, Rolando, Zhou, Honghong, Das, Rituparna, Miller, Jacqueline
Publicado 2021

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

por Leroux-Roels, Isabel, Davis, Matthew G, Steenackers, Katie, Essink, Brandon, Vandermeulen, Corinne, Fogarty, Charles, Andrews, Charles P, Kerwin, Edward, David, Marie-Pierre, Fissette, Laurence, Vanden Abeele, Carline, Collete, Delphine, de Heusch, Magali, Salaun, Bruno, De Schrevel, Nathalie, Koch, Juliane, Verheust, Céline, Dezutter, Nancy, Struyf, Frank, Mesaros, Narcisa, Tica, Jelena, Hulstrøm, Veronica
Publicado 2022